AstraZeneca Delivers Strong FY 2025 Results; Q4 Revenue Exceeds Expectations, Shares Gain

AstraZeneca's (LON: AZN) full-year 2025 results showcase robust commercial performance and successful pipeline execution, exceeding expectations and setting a positive tone for 2026.

Q4 revenue topped consensus estimates, coming in at $15.503 billion against an expected $15.44 billion, sending shares aroiund 2% higher at the open on Tuesday.

Headline Numbers:

Revenue: Total revenue for FY 2025 reached $58.739 billion, up 8% at constant exchange rates (CER). Q4 2025 revenue stood at $15.503 billion, a 2% increase CER. Product sales drove the majority of revenue, reaching $55.573 billion for the year, a 9% increase CER. Alliance revenue also contributed significantly, rising 38% CER to $3.067 billion.

Profit & Margins: Reported EPS for FY 2025 surged 43% to $6.60, while Q4 2025 EPS increased 47% to $1.50. Core EPS, which excludes certain items, increased 11% to $9.16 for the full year and 1% to $2.12 for Q4. Core operating profit increased 9%.

Cash & Balance Sheet: Details on cash and balance sheet specifics were not provided in this release. However, the company's strong performance suggests a healthy financial position, allowing for continued investment in research and development.

AstraZeneca is rewarding shareholders with a second interim dividend of $2.17 per share, bringing the total dividend for FY 2025 to $3.20 per share, a 3% increase over the previous year. This reflects the company's confidence in its financial stability and future growth prospects.

Driver Breakdown:

• Oncology Leadership: Oncology remains a key growth driver, contributing significantly to the overall revenue increase.
• Geographic Breadth: Growth was seen across all major geographic regions, demonstrating the company's global reach and diversified revenue streams.
• Pipeline Success: 16 positive Phase 3 readouts and 43 approvals in major regions over the past year highlight the strength and productivity of AstraZeneca's pipeline.

Pascal Soriot, Chief Executive Officer of AstraZeneca, stated, “In 2025 we saw strong commercial performance across our therapy areas and excellent pipeline delivery…The momentum across our company is continuing in 2026 and we are looking forward to the results of more than 20 Phase 3 trial readouts this year,” reinforcing the company’s commitment to innovation and growth.

Guidance for FY 2026 indicates continued optimism, with Total Revenue expected to increase by a mid-to-high single-digit percentage and Core EPS projected to increase by a low double-digit percentage. The Core Tax rate is expected to be between 18-22%. Furthermore, favorable foreign exchange rates could provide a low single-digit percentage boost to Total Revenue, with Core EPS growth remaining broadly similar.